All Press Releases
PILA PHARMA AB (publ) (FN STO: PILA) today publishes the Company´s year-end report for the period January – December 2025.
Malmö, 10 February 2026 The report can be found on the Company´s website: https://pilapharma.com/financial-reports/SUMMARY OF YEAR-END REPORT SECOND HALF YEAR (1 JULY- 31 DECEMBER 2025) Operating income amounted to TSEK 276 (107) The operating result (EBIT) totaled to TSEK -3 802 (-4 030) The result for the period totaled to TSEK -12 761 (-7 155) Earnings per share, basic and…
PILA PHARMA PREPARES CLINICAL TRIAL APPLICATION IN RARE DISEASE ERYTHROMELALGIA
Malmö, 09 February 2026 PILA PHARMA AB (publ) (FN STO: PILA) ("PILA PHARMA" or the "Company"), an innovative biotech company developing a novel oral, small molecule TRPV1 inhibitor, today announces that it has initiated preparations for a clinical trial application for a proof-of-concept study in the rare disease erythromelalgia. The ambition is to develop PILA PHARMA's oral TRPV1 inhibitor as…
PILA PHARMA ACCELERATES THE PUBLICATION OF THE INTERIM REPORT OF THE SECOND HALF OF 2025
Malmö, 05 February 2026 PILA PHARMA AB (publ) ("PILA PHARMA" or the "Company"), an innovative biotech company developing a novel oral, small molecule TRPV1 inhibitor, today announced that it will publish its interim report for the second half of 2025, on 10 February 2026, bringing forward the previously scheduled publication date of 26 February 2026. The reason for rescheduling is…